Davita Inc (NYSE:DVA) Given Average Rating of “Hold” by Brokerages

Shares of Davita Inc (NYSE:DVA) have been given a consensus recommendation of “Hold” by the twelve brokerages that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $64.74.

DVA has been the topic of a number of recent analyst reports. ValuEngine raised shares of Davita from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. William Blair reiterated a “buy” rating on shares of Davita in a research note on Thursday, June 20th. Deutsche Bank cut their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Robert W. Baird lowered shares of Davita from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $70.00 to $65.00 in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research note on Friday, May 10th.

A number of large investors have recently modified their holdings of DVA. Rehmann Capital Advisory Group increased its stake in shares of Davita by 467.3% during the first quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock worth $30,000 after buying an additional 458 shares during the period. Clearbridge Investments LLC increased its stake in shares of Davita by 63.5% during the first quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock worth $43,000 after buying an additional 310 shares during the period. CSat Investment Advisory L.P. increased its stake in shares of Davita by 54.0% during the first quarter. CSat Investment Advisory L.P. now owns 895 shares of the company’s stock worth $49,000 after buying an additional 314 shares during the period. Quadrant Capital Group LLC increased its stake in shares of Davita by 2,481.1% during the first quarter. Quadrant Capital Group LLC now owns 955 shares of the company’s stock worth $50,000 after buying an additional 918 shares during the period. Finally, Employers Holdings Inc. purchased a new stake in shares of Davita during the second quarter worth approximately $56,000. Institutional investors own 87.54% of the company’s stock.

NYSE DVA traded down $0.77 during trading hours on Monday, reaching $58.92. The company had a trading volume of 4,818,606 shares, compared to its average volume of 2,998,700. The firm has a 50-day moving average price of $57.73. Davita has a 1-year low of $43.40 and a 1-year high of $79.11. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10. The company has a market capitalization of $9.54 billion, a PE ratio of 16.50, a P/E/G ratio of 0.57 and a beta of 1.59.

Davita (NYSE:DVA) last posted its earnings results on Thursday, August 1st. The company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.12. Davita had a net margin of 1.21% and a return on equity of 14.67%. The company had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.86 billion. During the same quarter in the prior year, the company posted $1.05 earnings per share. Davita’s revenue for the quarter was down 1.5% compared to the same quarter last year. As a group, research analysts forecast that Davita will post 4.74 EPS for the current fiscal year.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: What is Call Option Volume?

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.